CompletedNCT02624167
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
Medication studyAges 18–65India + United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Garden Grove and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 90
- Sponsor
- Newron Pharmaceuticals SPA
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, India
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02624167
- Official title
Show the full official title
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Get this study by email
Recruitment & locations
CompletedGarden Grove, United States · Berlin, United States · Chennai, India
2 more locations
- Madurai, India
- Bangalore, India
Questions about this study
Who is behind this study?
The study sponsor is Newron Pharmaceuticals SPA.
Did this study involve medication?
Yes. The study involved medication, including NW-3509A and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia